000			02218 a2200565 4500
005			20250516152706.0
264		0	_c20130827
008			201308s 0 0 eng d
022			_a1432-0843
024	7		_a10.1007/s00280-013-2168-z _2doi
040			_aNLM _beng _cNLM
100	1		_aEl-Khoueiry, Anthony
245	0	0	_aThe effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. _h[electronic resource]
260			_bCancer chemotherapy and pharmacology _cJul 2013
300			_a53-64 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAlanine _xadministration & dosage
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aCarcinoma, Hepatocellular _xblood
650	0	4	_aCohort Studies
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aFemale
650	0	4	_aHalf-Life
650	0	4	_aHepatic Insufficiency _xblood
650	0	4	_aHumans
650	0	4	_aLiver _xdrug effects
650	0	4	_aLiver Neoplasms _xblood
650	0	4	_aMale
650	0	4	_aMetabolic Clearance Rate
650	0	4	_aMiddle Aged
650	0	4	_aPatient Dropouts
650	0	4	_aProdrugs _xadministration & dosage
650	0	4	_aProtein Kinase Inhibitors _xadministration & dosage
650	0	4	_aReceptors, Fibroblast Growth Factor _xantagonists & inhibitors
650	0	4	_aReceptors, Vascular Endothelial Growth Factor _xantagonists & inhibitors
650	0	4	_aSeverity of Illness Index
650	0	4	_aTriazines _xadministration & dosage
700	1		_aPosey, James A
700	1		_aCastillo Ferrando, Juan Ramón
700	1		_aKrishnamurthi, Smitha S
700	1		_aSyed, Shariq
700	1		_aKollia, Georgia
700	1		_aWalters, Ian
700	1		_aFischer, Bruce S
700	1		_aMasson, Eric
773	0		_tCancer chemotherapy and pharmacology _gvol. 72 _gno. 1 _gp. 53-64
856	4	0	_uhttps://doi.org/10.1007/s00280-013-2168-z _zAvailable from publisher's website
999			_c22791840 _d22791840